MedTrace Logo

Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer

NCT02130700 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2018-05-07

No results posted yet for this study

Summary

The goal of this clinical study is to determine the safety and efficacy of VT-464, a lyase-selective inhibitor of CYP17, in patients with castration-resistant prostate cancer (CRPC) who have been previously treated with Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men with ER positive Breast Cancer.

Conditions

Interventions

DRUG

VT-464: given orally twice daily in 28-day cycles

Oral VT-464 given twice daily, in continuous 28-day cycles at the recommended Phase 2 dose

DRUG

VT-464: given orally once daily in 28-day cycles

Oral VT-464 given once daily, in continuous 28-day cycles at the recommended Phase 2 dose

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Innocrin Pharmaceutical

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2017-09-30
Completion
2017-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02130700 on ClinicalTrials.gov